

## What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following agents is classified as a reversible Bruton tyrosine kinase (BTK) inhibitor?**
  - Ibrutinib
  - Acalabrutinib
  - Zanubrutinib
  - Pirtobrutinib**
- 2. Which of the following agents has had its accelerated approval voluntarily withdrawn for patients with previously treated mantle cell lymphoma (MCL)?**
  - Acalabrutinib
  - Glofitamab
  - Ibrutinib**
  - Brexucabtagene autoleucl
- 3. Updated data from the Phase I/II BRUIN study evaluating pirtobrutinib in patients with previously treated MCL demonstrated which outcome below?**
  - Only patients with BTK inhibitor-naïve MCL exhibited tumor responses to pirtobrutinib
  - Only patients who had previously received a BTK inhibitor for MCL exhibited tumor responses to pirtobrutinib
  - Both patients with BTK-naïve MCL and those who had previously received a BTK inhibitor for MCL exhibited tumor responses to pirtobrutinib**
- 4. Three-year follow-up from the ZUMA-2 study of brexucabtagene autoleucl for relapsed/refractory MCL demonstrated which outcome?**
  - Median overall survival (OS) for the overall population was approximately 47 months
  - Median OS for the overall population was approximately 15 months
  - Median OS for patients achieving complete response (CR) was not reached
  - Median OS for patients achieving CR was 47 months
  - Both a and c**
  - Both b and d
- 5. Emerging data indicate that the TRANSCEND NHL 001 trial met its primary endpoint of overall response rate with which agent for patients with relapsed/refractory MCL?**
  - Zanubrutinib
  - Lisocabtagene maraleucl**
  - Glofitamab